Photo courtesy of Erasca.
Erasca is developing small molecule drugs and other therapies that target cancer-causing genes.

Photo courtesy of Erasca. Erasca is developing small molecule drugs and other therapies that target cancer-causing genes.

Erasca, a cancer therapeutics company seeking to eliminate cancer, has completed a $36 million extension of its Series B financing round, bringing its total Series B round to $236 million...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99